Teresa Healthcare has developed a transdermal therapeutic ulcer device, a combination product of drug and appliance enabled by electroporation (EPT). Transdermal drug delivery system integrated by EPT is able to maintain high concentration of drug in target ulcer tissues. It is sure to produce tremendous impact on increasing effects of conventional medicines on diabetes ulcer and other dermatosis, and further to have significant potential for promoting future drug preparation industry. Teresa Healthcare has currently been engaged in collaborative study on diabetes ulcer treatment with the Zhejiang University .
1.The device is a combination product of drug and appliance enabled by electroporation and ion delivery technology. The perfect synergetic functions make it possible to deliver drugs rapidly and effectively.
2. The micro-electronics make it safe to send stable current pulses of electricity, and accessible to control different modes of personal treatment.
3. The device offers a new vision to develop the combination product of drug and appliance.
Teresa Healthcare has applied for patent protection of “Hyaloplasm Acerbity Transdermal Delivery Therapeutic Device” in China (No. 200510024767.9) in 2005.